New potential for enhancing concomitant chemoradiotherapy with FDA approved concentrations of cisplatin via the photoelectric effect

Altundal, Y; Cifter, G; Detappe, Alexandre; Sajo, Erno; Tsiamas, Panagiotis; Zygmanski, Piotr; Berbeco, R.; Cormack, Robert A.; Makrigiorgos, Mike; Ngwa, Wilfred

doi:10.1016/j.ejmp.2014.11.004

Cited by 17 publications

(29 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3 [21,22]. The empirical relation between the electron energy loss with distance traveled dE / dR (keV/μm) and the residual range R (μm) ( R = R tot − r e ) is based on Cole’s formula, where R tot is the total range of the electron for a kinetic energy E and r e is the distance from the electron emission site [23]:

\frac{d E}{d R} = 3.316 {(R + 0.007)}^{- 0.435} - 0.0055 R^{0.33} .

…”

Section: Methodsmentioning

confidence: 99%

Potential of using cerium oxide nanoparticles for protecting healthy tissue during accelerated partial breast irradiation (APBI)

et al. 2016

Self Cite

View full text Add to dashboard Cite

The purpose of this study is to investigate the feasibility of using cerium oxide nanoparticles (CONPs) as radical scavengers during accelerated partial breast irradiation (APBI) to protect normal tissue. We hypothesize that CONPs can be slowly released from the routinely used APBI balloon applicators—via a degradable coating—and protect the normal tissue on the border of the lumpectomy cavity over the duration of APBI. To assess the feasibility of this approach, we analytically calculated the initial concentration of CONPs required to protect normal breast tissue from reactive oxygen species (ROS) and the time required for the particles to diffuse to various distances from the lumpectomy wall. Given that cerium has a high atomic number, we took into account the possible inadvertent dose enhancement that could occur due to the photoelectric interactions with radiotherapy photons. To protect against a typical MammoSite treatment fraction of 3.4 Gy, 5 ng-g−1 of CONPs is required to scavenge hydroxyl radicals and hydrogen peroxide. Using 2 nm sized NPs, with an initial concentration of 1 mg-g−1, we found that 2–10 days of diffusion is required to obtain desired concentrations of CONPs in regions 1–2 cm away from the lumpectomy wall. The resultant dose enhancement factor (DEF) is less than 1.01 under such conditions. Our results predict that CONPs can be employed for radioprotection during APBI using a new design in which balloon applicators are coated with the NPs for sustained/controlled in-situ release from within the lumpectomy cavity.

show abstract

\frac{d E}{d R} = 3.316 {(R + 0.007)}^{- 0.435} - 0.0055 R^{0.33} .

…”

Section: Methodsmentioning

confidence: 99%

Potential of using cerium oxide nanoparticles for protecting healthy tissue during accelerated partial breast irradiation (APBI)

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…In this work, only the contribution of photoelectrons was taken into account for the calculation of dose enhancement (Van den Heuvel et al 2010). Step by step explanation of the tumor voxel analytical calculations can be found in the previous publications (Ngwa et al 2010, Berbeco et al 2011, Altundal et al 2015). …”

Section: Methodsmentioning

confidence: 99%

Potential for enhancing external beam radiotherapy for lung cancer using high-Z nanoparticles administered via inhalation

et al. 2015

Self Cite

View full text Add to dashboard Cite

Nanoparticle-aided radiation therapy is emerging as a promising modality to enhance radiotherapy via the radiosensitizing action of high atomic number (Z) nanoparticles. However, the delivery of sufficiently potent concentrations of such nanoparticles to the tumor remain a challenge. This study investigates the dose enhancement to lung tumors due to high-Z nanoparticles (NPs) administered via inhalation during external beam radiotherapy. Here NPs investigated include: cisplatin nanoparticles (CNPs), carboplatin nanoparticles (CBNPs), and gold nanoparticles (GNPs). Using Monte Carlo–generated megavoltage energy spectra, a previously employed analytic method was used to estimate dose enhancement to lung tumors due to radiation-induced photoelectrons from the NPs administered via inhalation route (IR) in comparison to intravenous (IV) administration. Previous studies have indicated about 5% of FDA-approved cisplatin concentrations reach the lung via IV. Meanwhile recent experimental studies indicate that 3.5–14.6 times higher concentrations of NPs can reach the lung by IR compared to IV. Taking these into account, the dose enhancement factor (DEF) defined as the ratio of the radiotherapy dose with and without nanoparticles was calculated for a range of NPs concentrations and tumor sizes. The DEF for IR was then compared with that for IV. For IR with 3.5 times higher concentrations than IV, and 2 cm diameter tumor, clinically significant DEF values of up to 1.19, 1.26, and 1.51 were obtained for CNPs, CBNPs and GNPs. In comparison values of 1.06, 1.08, and 1.15 were obtained via IV administration. For IR with 14.6 times higher concentrations, even higher DEF values were obtained e.g. 1.81 for CNPs. Results also showed that the DEF increased with increasing field size or decreasing tumor volume, as expected. The results of this work indicate that IR administration of targeted high-Z CNPs/CBNPs/GNPs could enable clinically significant DEF to lung tumors compared to IV administration during external beam radiotherapy. For FDA approved concentrations of CNPs or CBNPs considered, this could allow for additional dose enhancement to tumors via photoelectric mechanism during concomitant chemoradiotherapy.

show abstract

“…Meanwhile, the tumor sub-volume or voxel away from the tumor vasculature was modeled using dimensions of 10μm × 10 μm × 10 μm, as in a recent study (Fig. 1) [10]. When the high-Z nanoparticles (NPs) are exposed to radiotherapy photons in the keV range, photo/Auger electrons are emitted as a result of photoelectric interaction.…”

Section: Methodsmentioning

confidence: 99%

Nanoparticle-aided Radiotherapy for Retinoblastoma and Choroidal Melanoma

et al. 2015

Self Cite

View full text Add to dashboard Cite

This work investigates the dosimetric feasibility of employing gold nanoparticles (AuNPs) or carboplatin nano-particles (CNPs) to enhance radiotherapy (RT) treatment efficacy for ocular cancers: retinoblastoma (Rb) and choroidal melanoma (CM), during kV-energy internal and external beam radiotherapy. The results predict that substantial dose enhancement may be achieved by employing AuNPs or CNPs in conjunction with radiotherapy for ocular cancer using kV-energy photon beams. Brachytherapy sources yield higher dose enhancement than the external beam in kV energy range. However, the external beam has the advantage of being non-invasive

show abstract

New potential for enhancing concomitant chemoradiotherapy with FDA approved concentrations of cisplatin via the photoelectric effect

Cited by 17 publications

References 41 publications

Potential of using cerium oxide nanoparticles for protecting healthy tissue during accelerated partial breast irradiation (APBI)

Potential of using cerium oxide nanoparticles for protecting healthy tissue during accelerated partial breast irradiation (APBI)

Potential for enhancing external beam radiotherapy for lung cancer using high-Z nanoparticles administered via inhalation

Nanoparticle-aided Radiotherapy for Retinoblastoma and Choroidal Melanoma

Contact Info

Product

Resources

About